Clinical assessment of BIOCERA-VET in complications of fracture associated with an impaired bone healing Five participating centers in Italy Study endorsed by Key Opinion Leaders in
Acceleration of R&D programs: a new product marketed in the first half of 2023 Pursue of the positioning in high added-value indications New scientific and clinical promotional actions
Agreement signed with Vetpharma, a highly qualified team with a robust distribution network in support of commercialization BIOCERA-VET now available in all continents New high potential
Regulatory News: TheraVet (ISIN: BE0974387194 ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, is delighted to announce its
TheraVet participation in several reference veterinary congresses BIOCERA-VET nominated for the Veterinary Innovation Award, Equipment and Devices category, at the AFVAC 2022 conference (France) Regulatory